EI
RYTM icon

EAM Investors’s Rhythm Pharmaceuticals RYTM Stock Holding History

EAM Investors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-57,327
Closed -$6.14M – 363
2025
Q4 		$6.14M Sell
57,327
-1,153
-2% -$122K 0.68% 33
2025
Q3 		$5.81M Buy
+58,480
New +$5.43M 0.67% 38
2025
Q2 		– Sell
-45,108
Closed -$2.39M – 336
2025
Q1 		$2.39M Sell
45,108
-17,970
-28% -$997K 0.41% 124
2024
Q4 		$3.53M Buy
+63,078
New +$3.48M 0.5% 101
2023
Q1 		– Sell
-164,695
Closed -$4.8M – 347
2022
Q4 		$4.8M Sell
164,695
-34,004
-17% -$874K 0.99% 3
2022
Q3 		$4.87M Buy
+198,699
New +$3.7M 1.06% 4

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

EAM Investors's RYTM Position: Q1 2026 in Review

EAM Investors sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 57,327 shares — an estimated $6.14M sold.

EAM Investors first reported a position in RYTM in Q3 2022 and held it in 6 quarters. The position peaked at $6.14M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • EAM Investors reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • EAM Investors sold 57,327 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $6.14M.
  • EAM Investors first reported a position in Rhythm Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • EAM Investors's Rhythm Pharmaceuticals position peaked at $6.14M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.